Evidence map›Paper›PMID 35385156›Full record

ArticleJournal of clinical laboratory analysis2022

Application of collagen triple helix repeat containing-1 and mitotic spindle apparatus antibody in small cell lung cancer diagnosis.

Yuhan Liu, Tingting Hu, Xu Li, Xiaohang Li, Jianlin Yu, Yang Wu, Simei Chen, Liming Tan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuhan LiuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Tingting HuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xu LiDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xiaohang LiDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Jianlin YuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yang WuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Simei ChenDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Liming TanDepartment of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China.ORCID https://orcid.org/0000-0002-1888-3476
Nanchang University · CN

Funding

National Nature Science Foundation of China under Grant 81760382the Innovative Special Fund Project for Graduate Students of Jiangxi Province YC2020-S045the Key Research and Development Program of Jiangxi Province-General projects 20192BBG70033
6 · The paper itself

Abstract

backgroundThe clinical significance of serum collagen triple helix repeat protein-1 (CTHRC1) and mitotic spindle apparatus antibody (MSA) in the diagnosis of small cell lung cancer (SCLC).

methodsOf the 229 lung tumor patients selected, 62 patients were divided into SCLC, 94 patients with non-small cell lung cancer (NSCLC), and 73 patients with benign lung disease (BLD). The health controls (HC) had a span of 66 cases with normal physical condition. The serum extracted from each participator and enzyme-linked immunosorbent assay was adopted for measuring the serum CTHRC1 and MSA; in the meantime, automatic electrochemiluminescence immunoassay was used for the quantitative determination of serum NSA and CEA. And then, the differences in serum CTHRC1, MSA, NSE, and CEA were compared among involved groups.

results① Compared with other groups, the concentrations of CTHRC1, MSA, and NSE showed a marked increase in the group of SCLC (all p < 0.01). Especially for SCLC patients with lymph node metastasis, CTHRC1 provided a notably higher level than those without metastasis. ② CTHRC1 and MSA established a diagnostic criterion with the specificity of 90.99% and 86.27% for SCLC, respectively. ③ In series, the specificity of CTHRC1 and NSE was the highest (99.30%), while MSA and NSE had the highest sensitivity (96.72%) in parallel. ④ Both CTHRC1 and MSA were hazardous factors interconnected with SCLC.

conclusionSerum CTHRC1 and MSA had a more exciting prospect of application. When used in conjunction with NSE and CEA, they could optimize the clinical diagnosis value of SCLC.

Indexed as

Carcinoma, Non-Small-Cell LungExtracellular Matrix ProteinsLung NeoplasmsSmall Cell Lung CarcinomaBiomarkers, TumorCarcinoembryonic AntigenCollagenHumansSpindle ApparatusBiomarkers, TumorCarcinoembryonic AntigenCollagenCTHRC1 protein, humanExtracellular Matrix Proteinscollagen triple helix repeat containing-1mitotic spindle apparatus antibodyneuron-specific enolasenon-small cell lung cancersmall cell lung cancer

Identifiers

PMID35385156
PMCPMC9102652
OpenAlexW4224241727

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.